Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 393

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 393
---
 stakeholders. As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, including strategic partnerships, out licensing assets of the Company, and other future strategic actions. Several strategic partnerships discussions are currently under way and in advanced stages of negotiations. As always, NLS continued to approach the sleep medicine market from a holistic perspective. According to “Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments — Forecast to 2030” the global sleep medicine market is estimated to increase to more than $100 billion by 2030, with narcolepsy accounting for over $6 billion by 2030. License Agreements Pegasus Advanced Research SAS License Agreement In February 2015, Pegasus Advanced Research, then named NeuroLife -SciencesSAS, or Pegasus, a company owned by certain of NLS’s founders, who are also shareholders, including Eric Konofal, Eric -JeanDesbois, Bruno Figadere and NLS’s Chief Executive Officer, Alexander Zwyer, or the Pegasus Founders, entered into a license agreement with AP -HP, or the AP -HPLicense Agreement, to obtain a worldwide, sub -licensablelicense, covering four different compounds, which included the use of mazindol for the treatment of ADHD, or the Licensed Compounds. As part of the AP -HPLicense Agreement, Pegasus was given an option to purchase the Licensed Compounds. In February 2016, after the AP -HPLicense Agreement was assigned and transferred to NLS -1, pursuant to an Assignment and Transfer Agreement, or the ATA, NLS -1purchased the Licensed Compounds from AP -HPfor an aggregate consideration of approximately 2.65 million euros, including reimbursement of certain expenses. On April 1, 2017 and September 20, 2019, the parties entered into subsequent amendments of the ATA, or the First Amendment to the ATA and the Second Amendment to the ATA, respectively. Under the Second Amendment to the ATA, NLS agreed to pay Pegasus a royalty of 1.8% of annual net sales (including sublicensee sales) realized upon the commercialization of products developed on the basis of the Licensed Compounds during the terms of their respective patents; provided, however, that under certain circumstances, the rate of the royalty payment will decrease. For instance, if a